echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > The viral RNA polymerase inhibitor AT-527 treats COVID-19, and Chugai Pharmaceuticals will be responsible for the development and sale in Japan

    The viral RNA polymerase inhibitor AT-527 treats COVID-19, and Chugai Pharmaceuticals will be responsible for the development and sale in Japan

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Japan's Chugai Pharmaceutical Co., Ltd. announced today that it has reached a licensing agreement with Roche to develop and market a new oral anti-COVID-19 candidate drug, AT-527, in Japan.
    AT-527 is a research oral pyrethroid nucleotide pre-drug that has been shown to have antiviral activity in vitro and in vivo for several single-stranded RNA viruses, including human yellow and coronavirus.
    this highly selective pre-nucleotide drug is designed to uniquely inhibit viral RNA-dependent RNA polymerases, an enzyme essential for replicating RNA viruses.
    activity and safety of AT-527 has been confirmed in Phase II clinical studies in patients with hepatitis C and in preclinical testing of SARS-CoV2 virus.
    note that the AT-527 has not been licensed or approved for any use in any country.
    developed the AT-527 in partnership with Roche and Atea.
    approval, Atea will distribute the AT-527 in the United States, while Roche will be responsible for global manufacturing and distribution outside the United States.
    under a licensing agreement between Roche and Chugai Pharmaceuticals, Chugai Pharmaceuticals acquired exclusive development and sales rights for the AT-527 in Japan.
    , phase II clinical studies are being conducted in patients requiring hospitalization in moderate COVID-19 and mild to moderate COVID-19 patients who are not hospitalized.
    is expected to begin a Phase III clinical study in the first half of 2021 to assess the efficacy and safety of AT-527 in patients with mild or moderate COVID-19.
    Osamu Okuda, president and chief operating officer of Chugai, said: "COVID-19 has not shown signs of slowing down and new treatment options are still needed."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.